Epstein-Barr Virus (EBV)-Associated Diseases research hub
5 indexed studies · 3 currently recruiting
- active not recruitingPHASE2
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
This study is looking at a new treatment called tabelecleucel for diseases linked to the Epstein-Barr virus (EBV). These can include certain cancers or conditions where the immune system isn't working properly. The study wants to see how well tabelecleucel works and if it's safe.
United States · Austria · Belgium - recruitingPHASE2
Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor
This study looks into a new way of doing stem cell transplants for children aged 1 to 19 with sickle cell disease. It aims to make this life-changing treatment available to more children, especially if their donor's blood type doesn't perfectly match theirs.
Canada - recruitingPHASE2
Loratadine for the Prevention of G-CSF-related Bone Pain
This study looks at whether loratadine, an allergy medicine, can help prevent bone pain in people having a stem cell transplant for lymphoma or multiple myeloma. We're comparing it to a dummy pill to see if it makes a difference.
Canada - recruitingPHASE3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
This study is testing a new medicine, tabelecleucel, for people who have a condition called EBV+ PTLD. This condition can happen after an organ transplant or a stem cell transplant and treatment with rituximab hasn't worked. The study wants to see if tabelecleucel is safe and effective.
United States · Australia · Austria - active not recruiting
Delirium in Children Undergoing Stem Cell Transplantation
This study looks at a temporary change in thinking called delirium in children having stem cell transplants. We want to find out how often it happens, why it happens, and how it affects children, aiming to reduce it. It's for children aged up to 21 undergoing this treatment.
United States · Canada